We are grateful to the Prostate Cancer Foundation @PCFnews for inviting us to the #PCFRetreat26 this past weekend. Dr. Chuck Link, our Executive Chairman and Chief Innovation Officer, was selected to deliver a special lecture on the latest developments in our SYNC-T immunotherapy platform and the ongoing LEGION-100 Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC). It was a privilege to join leading researchers, clinicians, and industry experts in the field. #ScientificRetreat #LEGION100 #SYNCT #ProstateCancer #immunotherapy

#ICYMI: Syncromune’s Chief Medical Officer, Urology, Gerald Andriole, M.D., joined Keith Crawford, M.D., Ph.D., of the Prostate Health Education Network (PHEN) @RAPCancer for an engaging fireside chat on SYNC-T Therapy SV-102 and the ongoing LEGION-100 Phase 2 clinical trial. Three key takeaways from the discussion: • A differentiated drug-device approach: SYNC-T combines image-guided partial tumor cryolysis with intratumoral infusion of the investigational multi-target drug SV-102 through the same device pathway. The approach is designed to bring tumor antigens, drug and immune cells together in regional lymphatics to support a systemic anti-tumor immune response. • Promising early clinical findings: Previously reported Phase 1 results in metastatic prostate cancer demonstrated encouraging clinical activity with a manageable safety profile, supporting continued evaluation of SYNC-T Therapy SV-102. • Currently in Phase 2: LEGION-100 is evaluating the safety, anti-tumor activity and dose-optimization of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer. Watch the full conversation to hear Drs. Andriole and Crawford discuss the science behind #SYNCT, the Phase 1 experience and the goals of #LEGION100: bit.ly/3URQDaU SYNC-T Therapy SV-102 is investigational and has not been approved or determined to be safe or effective. #ProstateCancer #ClinicalTrials #Immunotherapy #Oncology #CancerResearch #DrugDeviceCombination

At #CIRSE2026, Stephen Kee, M.D., EVP, Clinical, Medical & Business Operations, EMEA, reviewed the Phase 1 data on our investigational SYNC-T™ platform, a novel combination approach that pairs single-needle partial cryolysis with direct intratumoral infusion of SV-102, an investigational immunotherapy. By combining local tumor destruction with localized immunotherapy delivery, SYNC-T™ Therapy SV-102 is designed to stimulate a systemic immune response while limiting systemic drug exposure. The approach is now being evaluated in Syncromune’s Phase 2 LEGION-100 trial, which is actively enrolling patients across the U.S., with international expansion planned. Learn more about the LEGION-100 trial: legion100trial.com #CIRSE2026 #InterventionalRadiology #IntratumoralImmunotherapy #ProstateCancer #ClinicalTrials #mCRPC

June is Cancer Immunotherapy Month, an opportunity to recognize the scientific innovation, clinical research, and patient participation that continue to advance the field of cancer treatment. At Syncromune®, we are proud to contribute to this progress through the development of SYNC-T™ and by engaging with the broader oncology community. Most recently, we participated in the inaugural Intratumoral Immunotherapy Symposium hosted by @GustaveRoussy in collaboration with @UTMDAnderson, where experts from across academia, biotechnology, interventional oncology, and regulatory science came together to discuss the future of intratumoral immunotherapy. Scientific collaboration and knowledge sharing are essential to accelerating innovation and advancing new treatment approaches for patients. Through our ongoing research efforts, we continue to evaluate the potential of #SYNCT, an investigational in situ intratumoral combination drug/device immunotherapy designed to synchronize the location of antigens, our multi-target drug, and immune cells to potentially drive a systemic anti-tumor response while minimizing systemic drug exposure and toxicity. We are currently evaluating SYNC-T Therapy SV-102 in our Phase 2 LEGION-100 clinical trial (#LEGION100) in patients with metastatic castration-resistant prostate cancer (#mCRPC). This Cancer Immunotherapy Month, we recognize and thank the patients, caregivers, investigators, research teams, and healthcare professionals whose commitment makes clinical progress possible. Their contributions help drive innovation and shape the future of cancer care. Learn more about LEGION-100: legion100trial.com #CancerImmunotherapyMonth #IntratumoralImmunotherapy #SYNCT #Syncromune #ClinicalResearch #OncologyInnovation #Biotech #mCRPS #EndCancer

We're looking forward to participating in the inaugural Intratumoral Immunotherapy Symposium, hosted by @GustaveRoussy in conjunction with @UTMDAnderson on June 11–12 in Villejuif, Paris, France. As the first international meeting dedicated exclusively to intratumoral immunotherapy, the symposium will bring together leaders from academia, biotechnology, interventional oncology, and regulatory science to discuss the mechanics of local delivery and localized immune modulation. #Syncromune Executive Chairman and Cofounder, Charles Link, MD, will present on the use of a multi-modal assessment approach to address efficacy following intratumoral immunotherapy . Dr. Link will also share the multi-modality solution used in a case study from a Phase 1 trial evaluating #SYNCT combination intratumoral therapy in metastatic castration-resistant prostate cancer (#mCRPC). Additionally, he will participate in a panel discussion focused on addressing the regulatory and strategic hurdles of intratumoral immunotherapy. We look forward to engaging with colleagues across the oncology community and contributing to important discussions to help shape the future of intratumoral cancer immunotherapy. #Immunotherapy #CancerImmnotherapy #Oncology #mCRPC #ClinicalResearch #IntratumoralImmunotherapy #GustaveRoussy #MDAndersonCancerCenter #SYNCT #LocalizedImmunotherapy #MultimodalAssessment #Syncromune #EndCancer

Chicago, here we come! Syncromune is excited to be attending the @ASCO 2026 Annual Meeting at McCormick Place, where the oncology community comes together to shape the future of cancer care. Starting May 30th, visit us at Booth #37077 through June 1st to meet the team behind our #SYNCT immunotherapy platform and learn more about the LEGION-100 Phase 2 trial for men with metastatic castration-resistant prostate cancer #mCRPC. We are actively enrolling and seeking additional clinical trial sites. If you are interested in becoming a trial site, please stop by and talk to our clinical team! Learn more at LEGION100Trial.com. Our clinical, medical, scientific, and executive leadership teams will be onsite throughout the meeting, looking forward to meaningful conversations, new connections, and sharing how Syncromune is developing the SYNC-T platform that aims to synchronize the immune system to fight cancer throughout the body. If you are attending #ASCO26 this year, stop by and say hello, we would love to connect! See you in Chicago! #ASCO26 #Oncology #Immunotherapy #ProstateCancer #mCRPC #SYNCT #LEGION100

Research doesn't rise on its own. It rises because patients volunteer, physicians lean in, and innovators keep pushing what’s possible. On #ClinicalTrialsDay, Syncromune is proud to advance the #LEGION100 Phase 2 trial of SYNC-T SV-102 for men with metastatic castration-resistant prostate cancer (#mCRPC). #ResearchRising #CTD2026 #Oncology #Immunotherapy

Join us today at #ECIO2026 in Auditorium 3 @ 8:30am for Dr. Kee's presentation "Abscopal effects of an image-guided percutaneous combination device/drug immunotherapy approach to metastatic prostate cancer" during the SP 413 – Y90 and novel therapies session! #ECIO2026 #Syncromune #CancerImmunotherapy #ProstateCancer #Intratumoral #SYNCT

Syncromune is excited to be attending the #IPCS26 this year to connect with leading prostate cancer experts and share the latest on our novel SYNC-T in situ immunotherapy for metastatic solid tumors! We are currently enrolling our Phase 2 LEGION-100 trial for our lead candidate SV-102 in mCRPC. Learn more about referring a patient or becoming a trial site: legion100trial.com #ProstateCancer #CancerImmunotherapy #Syncromune #SYNCT

Check out our presentation at the European Conference on Interventional Oncology 2026! Syncromune is pleased to announce that Stephen Kee, MD, will deliver an oral presentation on the potential of SYNC-T Therapy SV-102 for the treatment of metastatic prostate cancer at ECIO 2026 in Basel. Our combination drug/device immunotherapy uses an image-guided percutaneous approach to place a cryo needle/infusion sheath system into a target tumor, utilizing the same device to perform both cryolysis and infusion of a multi-target drug directly into the lysed zone. The therapy aims to elicit a systemic anti-tumor response, empowering the immune system to recognize and attack both primary and metastatic lesions. We look forward to engaging with the interventional oncology community and sharing the future vision of our SYNC-T locoregional immunotherapeutic platform that is designed to tackle the toughest challenges in treating metastatic solid tumors. #ECIO2026 #InterventionalOncology #Immunotherapy #Oncology #SYNCT #Syncromune #ProstateCancer #Intratumoral

Ready to ‘Sync Up’ in San Diego? Meet Dr. Charles Link, Executive Chairman and co-founder of Syncromune, today (April 20) at the ongoing American Association for Cancer Research Annual Meeting 2026, Booth #3752. This is your opportunity to engage with a true pioneer in medical oncology and get a firsthand look at SYNC-T™, our intratumoral combination drug/device immunotherapy platform designed to drive a smarter, systemic immune response against cancer. We’re actively enrolling patients and expanding trial sites for LEGION-100, our Phase 2 study in men with metastatic castration-resistant prostate cancer (mCRPC). Interested in becoming a site or referring patients? Let’s talk! Stop by Booth #3752 today. You won’t want to miss the opportunity to ‘sync up’ with Chuck! Explore more: Legion100Trial.com #AACR26 #ProstateCancer #mCRPC #Oncology #CancerResearch #SYNCT

Visit us at the 2026 AACR Annual Meeting in San Diego to learn about SYNC-T™, our combination intratumoral drug/device immunotherapy platform. We are now enrolling and recruiting trial sites for our Phase 2 LEGION-100 trial in men with metastatic castration-resistant prostate cancer (mCRPC). Stop by Booth #3752. Learn more: Legion100Trial.com #AACR26 #ProstateCancer #mCRPC #Oncology #CancerResearch #SYNCT

We're heading to #AACR26! Syncromune will be at this year's American Association for Cancer Research Annual Meeting taking place April 17–22, 2026 in San Diego, and we'd love to ‘sync up.’ Stop by our Booth #3752 to learn more about SYNC-T™, our in situ combination drug/device immunotherapy platform designed to synchronize the immune system to recognize and destroy cancer throughout the body. LEGION-100, our ongoing Phase 2 clinical trial evaluating SYNC-T Therapy SV-102 in men with metastatic castration-resistant prostate cancer (mCRPC), is actively enrolling patients and recruiting clinical trial sites. Please connect with us if you are interested in becoming a clinical trial site or want to learn more about how you can refer your mCRPC patients. Whether you're a clinician, researcher, or simply passionate about advancing cancer care, we’d love the opportunity to discuss our novel treatment approach for metastatic solid tumors! Find us at AACR: Booth #3752 Learn more: Legion100Trial.com #AACR26 #Oncology #ProstateCancer #mCRPC #CancerImmunotherapy #ClinicalTrials #LEGION100 #SYNCT #Biotech

Thank you @GRUrology and #IPCU36 attendees for a great meeting! Syncromune's abstract "Effective Resolution of Bone Metastases in Subjects with Metastatic Prostate Cancer Using SYNC-T Therapy SV-102" was presented by Gerald Andriole, M.D. @uropro, Syncromune's Chief Medical Officer, Urology, and can be read here: lnkd.in/gaq8dqXf Syncromune is expanding on these data in the LEGION-100 Phase 2 trial for mCRPC, which is currently enrolling and recruiting trial sites. Visit legion100trial.com to learn more. #ProstateCancer #Syncromune #Immunotherapy #Urology #LEGION100

Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability. SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial. Details: bit.ly/48jYaU5

Today, Syncromune will present new Phase 1 data at #SUO25 highlighting resolution of bone metastases in men with advanced prostate cancer treated with SYNC-T Therapy SV-102. Don’t miss our poster #175 from 4:30-5:30pm MST! bit.ly/48jYaU5

Thanks to everyone who connected with us at #SITC2025! We’re expanding the LEGION-100 trial and welcome new investigator sites interested in advancing in situ combination immunotherapy for prostate cancer. Learn more at legion100trial.com or reach out at info@legion100trial.com #ClinicalResearch #Syncromune